GLP1R and Parkinson disease: The risk of serious adverse events and odds of treatment discontinuation were similar between groups, but GLP-1 RAs were associated with an increased risk of weight loss compared to placebo (risk ratio: 1.44; 95% CI: 1.04-1.99; <i>p</i> = 0.03).<h4>Conclusion</h4>GLP-1 RAs were not associated with improvements in motor or non-motor domains of PD.